Stocks & Investing
Fri, August 16, 2024
[ Fri, Aug 16th 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
Tue, June 25, 2024
[ Tue, Jun 25th 2024
] - WOPRAI
Thu, May 9, 2024
[ Thu, May 09th 2024
] - WOPRAI
Tue, March 12, 2024
[ Tue, Mar 12th 2024
] - WOPRAI
Tue, March 5, 2024
[ Tue, Mar 05th 2024
] - WOPRAI
Thu, February 22, 2024
[ Thu, Feb 22nd 2024
] - WOPRAI
Thu, November 9, 2023
[ Thu, Nov 09th 2023
] - WOPRAI
Mon, August 28, 2023
[ Mon, Aug 28th 2023
] - WOPRAI
Mon, August 14, 2023
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
Wed, May 24, 2023
[ Wed, May 24th 2023
] - WOPRAI
Mon, May 8, 2023
[ Mon, May 08th 2023
] - WOPRAI
Fri, April 14, 2023
[ Fri, Apr 14th 2023
] - WOPRAI
Tue, March 28, 2023
[ Tue, Mar 28th 2023
] - WOPRAI
Tue, February 7, 2023
[ Tue, Feb 07th 2023
] - WOPRAI
Wed, November 16, 2022
[ Wed, Nov 16th 2022
] - WOPRAI
[ Wed, Nov 16th 2022
] - WOPRAI
Tue, November 1, 2022
[ Tue, Nov 01st 2022
] - WOPRAI
Wed, September 28, 2022
[ Wed, Sep 28th 2022
] - WOPRAI
Wed, August 24, 2022
[ Wed, Aug 24th 2022
] - WOPRAI
Tue, August 16, 2022
[ Tue, Aug 16th 2022
] - WOPRAI
[ Tue, Aug 16th 2022
] - WOPRAI
Tue, May 10, 2022
[ Tue, May 10th 2022
] - WOPRAI
Wed, January 12, 2022
[ Wed, Jan 12th 2022
] - WOPRAI
Mon, November 22, 2021
[ Mon, Nov 22nd 2021
] - WOPRAI
Wed, November 10, 2021
[ Wed, Nov 10th 2021
] - WOPRAI
Tue, October 26, 2021
[ Tue, Oct 26th 2021
] - WOPRAI
Mon, August 2, 2021
[ Mon, Aug 02nd 2021
] - WOPRAI
Salim Syed Upgraded (ATRA) to Buy and Decreased Target to $18 on, Aug 16th, 2024
Salim Syed of Mizuho, Upgraded "Atara Biotherapeutics, Inc." (ATRA) to Buy and Decreased Target from $25 to $18 on, Aug 16th, 2024.
Salim has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Robert Burns of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, May 22nd, 2024
These are the ratings of the 2 analyists that currently disagree with Salim
- John Newman of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $13 on, Tuesday, August 13th, 2024
- Tommie Reerink of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $11 on, Wednesday, July 17th, 2024
